• Jump to navigation (n)
  • Jump to content
  • Sitemap
Novalgen Novalgen
  • About us
    • Back
    • Overview
    • Our mission
    • Our team
    • Our history
    • Our investors
    • Our values
    • Community support
    • Social responsibility
    • Partnership & collaborations
  • Our technologies
    • Back
    • Overview
    • Our antibodies
    • Auto-regulation platform
    • Key capabilities
  • Patients & families
    • Back
    • Overview
    • Treatments
    • Patient organisations
    • Clinical trials
    • About disease areas
  • Pipeline
  • News & publications
    • Back
    • Overview
    • News
    • Publications
  • Careers
    • Back
    • Overview
    • Vacancies
  • Contact

News

Explore
  • 2023
  • 2022
  • 2021
  • 2020

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors

Jan 09, 2023

Publications

Publications
Novalgen
  • About us
  • Our technologies
  • Patients & families
  • Pipeline
  • News
  • Careers
  • © Novalgen 2023
  • Privacy and cookies
  • Accessibility
  • Contact
  • LinkedIn
  • Home
  • About us
    • Back
    • About us
    • About us overview
    • Our mission
    • Our team
    • Our history
    • Our investors
    • Our values
    • Community support
    • Social responsibility
    • Partnership & collaborations
  • Our technologies
    • Back
    • Our technologies
    • Our technologies overview
    • Our antibodies
    • Auto-regulation platform
    • Key capabilities
  • Patients & families
    • Back
    • Patients & families
    • Patients & families overview
    • Treatments
    • Patient organisations
    • Clinical trials
    • About disease areas
  • Pipeline
  • News & publications
    • Back
    • News & publications
    • News & publications overview
    • News
    • Publications
  • Careers
    • Back
    • Careers
    • Careers overview
    • Vacancies
  • Contact